Evidence indicates that MYC directly drives glutamine uptake and catabolism by activating the expression of genes involved in glutamine metabolism, including ASCT2 and GLS.4,35–37 Recently, two independent studies reported that miR-137 suppresses glutamine metabolism by directly targeting SLC1A5 (ASCT2).21,24 We confirmed this mechanism in HNSCC. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.